In This Article:
Pacific Biosciences of California (NASDAQ:PACB) First Quarter 2025 Results
Key Financial Results
-
Revenue: US$37.2m (down 4.3% from 1Q 2024).
-
Net loss: US$426.1m (loss widened by 445% from 1Q 2024).
-
US$1.44 loss per share (further deteriorated from US$0.29 loss in 1Q 2024).
Our free stock report includes 3 warning signs investors should be aware of before investing in Pacific Biosciences of California. Read for free now.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Pacific Biosciences of California EPS Misses Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates significantly.
Looking ahead, revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Life Sciences industry in the US.
Performance of the American Life Sciences industry.
The company's share price is broadly unchanged from a week ago.
Risk Analysis
Before you take the next step you should know about the 3 warning signs for Pacific Biosciences of California that we have uncovered.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.